The chemical class known as C10orf12 Inhibitors comprises a variety of compounds that modulate the activity of C10orf12, also known as LCOR (Ligand Dependent Nuclear Receptor Corepressor). These inhibitors are conceptualized to target the integral roles of LCOR in gene expression regulation and its interaction with nuclear receptors. Primarily, these inhibitors are designed to influence LCOR's function as a corepressor, which involves mediating transcriptional repression in association with nuclear receptors. The main mechanism through which these inhibitors operate includes altering the interaction dynamics between LCOR and nuclear receptors. This can be achieved either by directly affecting LCOR's ability to bind these receptors or by modulating the receptor's conformation and activity, thereby impacting LCOR's regulatory role in gene expression. Such inhibition is significant, as it directly challenges LCOR's involvement in the transcriptional outcomes dependent on hormonal or ligand signaling, shifting the balance from repression to activation of target genes and influencing the physiological processes regulated by these receptors.
Furthermore, inhibitors in this class also include compounds that modulate broader signaling pathways and cellular processes associated with LCOR's function. This encompasses altering post-translational modifications of LCOR or nuclear receptors, thereby modifying their activities and interactions. Additionally, some inhibitors work by influencing downstream or upstream elements of the signaling pathways in which LCOR participates. This might involve modifying the chromatin landscape, affecting the recruitment of other coregulatory proteins, or intervening in related signaling cascades. Such indirect approaches highlight the interconnected nature of cellular signaling pathways, underscoring the need to understand the broader context of LCOR's role within the nuclear receptor signaling network. Overall, the development of C10orf12 (LCOR) inhibitors represents a sophisticated approach to dissect and influence the complex mechanisms of gene regulation mediated by nuclear receptor-corepressor interactions. These inhibitors serve as key tools for probing LCOR's function and offer insights into the intricate dynamics of transcriptional regulation. By targeting both the direct activities of LCOR and the broader network of interactions and pathways in which it operates, C10orf12 inhibitors demonstrate the intricate strategies necessary to effectively modulate key components within cellular regulatory systems, providing a window into the nuanced world of gene expression control.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen could possibly inhibit LCOR by altering estrogen receptor activity, impacting LCOR's corepressor function. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
Bicalutamide could possibly inhibit LCOR by modifying androgen receptor signaling, affecting LCOR's interaction with the receptor. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could possibly inhibit LCOR by affecting chromatin remodeling and gene expression, processes in which LCOR is involved. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat could possibly inhibit LCOR by altering gene expression regulation, a key pathway influenced by LCOR. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid could possibly inhibit LCOR by modulating retinoic acid receptor signaling, impacting LCOR's regulatory role. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Mifepristone could possibly inhibit LCOR by affecting glucocorticoid receptor activity, thereby influencing LCOR function. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516 could possibly inhibit LCOR by modulating peroxisome proliferator-activated receptor signaling, a pathway LCOR may be involved in. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone could possibly inhibit LCOR by influencing PPARγ pathways and LCOR's interaction with these receptors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 could possibly inhibit LCOR by affecting the MAPK/ERK pathway, impacting LCOR's regulation of gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could possibly inhibit LCOR by modulating JNK signaling, a pathway that might intersect with LCOR's regulatory mechanisms | ||||||